The Alcon portfolio of complementary presbyopia-mitigating IOLs was developed to give surgeons more ways to provide more patients with exceptional vision. The AcrySof IQ PanOptix and PanOptix Toric Trifocal IOLs featuring ENLIGHTEN Technology make 20/20 vision at near, intermediate, and distance a possibility for your patients.*†1
AcrySof IQ Vivity and Vivity Toric IOLs featuring X-WAVE Technology are the first nondiffractive EDOF IOLs, delivering monofocal-quality distance, excellent intermediate, and functional near vision with a monofocal-like visual disturbance profile.2
How do these two lenses fit into your practice?
“I find that Vivity simplifies my conversation with patients regarding choices with cataract surgery. Now, a much broader pool of patients are candidates for presbyopia-mitigating IOLs.”
“PanOptix provides an excellent solution for patients desiring independence from glasses in the intermediate to near range.1 I usually identify those patients with two key questions: How often do you read or do fine near tasks, and are you okay with the possibility of seeing rings around lights at night?
Patients who are candidates for Vivity are usually those who state that they are active, do not consider glasses-free reading a priority, and/or are complaining of glare and halos that they are trying to eliminate.”2
“Vivity is my preferred choice for patients and surgeons who desire premium outcomes with an improved range of vision, low risk of visual disturbances, and no regrets if the eye health changes in the future. It allows me to offer a presbyopia-mitigating option to patients that fall just outside my comfort zone for a diffractive optic due to patient expectations, exam findings, or possible changes in their future ocular health.”
-Cathleen McCabe, MD
1. AcrySof IQ PanOptix Directions for Use.
2. AcrySof IQ Vivity Extended Vision Intraocular Lenses. Product Information. Alcon Laboratories, Inc.
*Based on mean value of binocular defocus from curve at near, intermediate, and distance at 6 months (n=127).
† Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 Early Treatment Diabetic Retinopathy Study chart letters in the line were identified correctly.
AcrySof® Family of Single-Piece IOLs (AcrySof® UV, AcrySof® IQ, AcrySof® IQ Toric, AcrySof® IQ ReSTOR®, AcrySof® IQ ReSTOR® Toric, AcrySof® IQ PanOptix®, AcrySof® IQ PanOptix® Toric AcrySof® IQ Vivity™ and AcrySof® IQ Vivity™ Toric IOLs)
Important Product Information
CAUTION: Federal law restricts these devices to sale by or on the order of a physician.
The family of AcrySof® single-piece intraocular lenses (IOLs) includes AcrySof® UV-absorbing IOLs (“AcrySof® UV”), AcrySof® IQ, AcrySof® IQ Toric, AcrySof® IQ ReSTOR®, AcrySof® IQ ReSTOR® Toric, AcrySof® IQ PanOptix® and AcrySof® IQ PanOptix® Toric IOLs. Each of these IOLs is indicated for visual correction of aphakia in adult patients following cataract surgery. In addition, the AcrySof Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery. The AcrySof IQ ReSTOR IOLs are for cataract patients with or without presbyopia, who desire increased spectacle independence with a multifocal vision. The AcrySof® IQ PanOptix® lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. The AcrySof® IQ Vivity™ lens mitigates the effects of presbyopia by providing an extended
depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity.
All of these IOLs are intended for placement in the capsular bag.
General cautions for all AcrySof® and AcrySof® UV IOLs:
Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting any IOL in a patient with any of the conditions described in the Directions for Use that accompany each IOL. Caution should be used prior to lens encapsulation to avoid lens decentration or dislocation. Physicians should target emmetropia, and ensure that IOL centration is achieved.
Additional cautions associated with AcrySof® IQ ReSTOR® and AcrySof® IQ PanOptix® IOLs: Some patients may experience visual disturbances and/or discomfort due to multifocality, especially under dim light conditions. These may include some perceptions of halos or starbursts, as well as other visual symptoms. Therefore, patients implanted with multifocal IOLs should exercise caution when driving at night or in poor visibility conditions. A reduction in contrast sensitivity may occur in low light conditions. Spectacle independence rates vary with all multifocal IOLs; as such, some patients may need glasses when reading small print or looking at small objects. Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning). Posterior capsule opacification (PCO), may significantly affect the vision of patients with multifocal IOLs sooner in its progression than patients with monofocal IOLs.
Additional cautions associated with AcrySof® IQ Vivity™ IOL:
Most patients implanted with the AcrySof® IQ Vivity™ IOL are likely to experience significant loss of contrast sensitivity as compared to a monofocal IOL. Therefore, it is essential that prospective patients be fully informed of this risk before giving their consent for implantation of the AcrySof® IQ Vivity™ IOL. In addition, patients should be warned that they will need to exercise caution when engaging in activities that require good vision in dimly lit environments, such as driving at night or in poor visibility conditions, especially in the presence of oncoming traffic. It is possible to experience very bothersome visual disturbances, significant enough that the patient could request explant of the IOL. In the AcrySof® IQ Vivity™ IOL clinical study, 1% to 2% of AcrySof® IQ Vivity™ IOL patients reported very bothersome starbursts, halos, blurred vision, or dark area visual disturbances; however, no explants were reported.
Additional cautions associated with AcrySof® IQ Toric, AcrySof® UV Toric ReSTOR® Toric, AcrySof® IQ PanOptix® Toric,
and AcrySof® IQ Vivity™ Toric IOLs:
Optical theory suggests that, high astigmatic patients (i.e. > 2.5 D) may experience spatial distortions. Possible toric IOL related factors may include residual cylindrical error or axis misalignments. Toric IOLs should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. Prior to surgery, physicians should provide prospective patients with a copy of the appropriate Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with the these IOLs.
Refer to the Directions for Use labeling for the specific IOL for a complete list of indications, warnings and precautions.
© 2021 Alcon Inc. 5/21 US-ACP-2100077